Instructions for Codelac Neo (Butamirate)
English product name
Codelac NEO
Release form
composite material with modif release film coating, 50 mg: 10, 20, 30 or 50 pcs
Description Codelac Neo:
Modified release pills coated with a white film sheath, round, double-convex; On the cross section of the tablet is white or almost white.
1 tab.
butamirate citrate 50 mg
Auxiliary substances:
lactose monohydrate (dairy sugar) - 241 mg,
hypromellose (metocel-K4M) - 85 mg,
talc - 4 mg, magnesium stearate - 4 mg,
silicon dioxide colloidal (aerosyl) - 6 mg,
povidone low molecular (polyvinylpyrrolidone low molecular) - 5 mg.
Film sheath composition: Opadray white (Opadray II white 57M280000) (including hypromellose - 5.58 mg, titanium dioxide - 4.86 mg, polydextrose - 4.68 mg, talc - 1.26 mg, maltodextrin / dextrin - 0.9 mg, glycerin / glycerol - 0.72 mg) - 18 mg.
Release form
syrup 7.5 mg/5 ml: fl 100 ml or 200 ml TBSP
Description Codelac Neo:
Syrup in the form of a colorless liquid with vanilla smell.
5 ml
butamirate citrate 7.5 mg
Auxiliary substances:
sorbitol (Neosorb 70/70 B, sorbitol) - 2025 mg,
glycerol (glycerin) - 1450 mg,
ethanol 95% (ethyl alcohol 95%) - 12.69 mg,
sodium saccharinate - 3 mg,
benzoic acid - 5.75 mg,
vanillin - 3 mg,
sodium hydroxide solution 30% - 1.55 mg,
water purified - up to 5 ml.
100 ml - dark glass bottles (1) complete with measuring spoon - cardboard packs.
200 ml - dark glass bottles (1) complete with measuring spoon - cardboard packs.
ATC codes
R05DB13 Butamirate
Clinical-pharmacological groups / Group affiliation
Anti-cough preparation
Active substance
butamirate citrate
Pharmacotherapy group
Anti-cough means of central action
Testimony Codelac Neo:
- Treatment of dry cough of different etiology:
- for cough suppression during pre- and post-operative period,
- during surgical procedures,
- bronchoscopy,
- pertussis.
Method of use, course and dosage Codelac Neo:
To be taken inside.
The dose is set individually, depending on the dosage form used and the patient's age.
Use in children
Contraindication: Children's age: up to 2 months (for drops), up to 3 years (for syrup), up to 12 years (for tablets with modified release).
Nosology Butamirate (ICD codes)
A37
Koklyush
R05
Cough
Z51.4
Preparatory procedures for follow-up treatment or examination not classified elsewhere
Pharmacological effect Codelac Neo:
Anti-cough means of central action. Butamirate is not an opium alkaloid. Does not form addictions or addictions.
Inhibits cough, having a direct effect on the cough center. It has expectorant, moderate bronchodilating and anti-inflammatory effects. It promotes breathing relief, improves spirometry (reduces respiratory resistance) and blood oxygenation.